

BC Kidney Days 2018 Provincial Update

Dr. Adeera Levin MD FRCPC CM Executive Director, BC Renal Agency

Professor of Medicine UBC

November 1, 2018





Personalized Kidney Care

Overview

- Kidney Disease in BC
- BC's Kidney Care Model: Unique Nationally & Internationally
 - Structure and Function
- A Renewed Strategic Focus



Optimal Patient Experience and Outcomes Innovation and Research in Renal Care Sustainable Funding Solutions The Right Technical Solutions A Sustainable Renal Community



Check your kidney health online:







KIDNEY DISEASE IN BRITISH COLUMBIA





15581

3264

death sentence. Today, people with kidney disease can live productive, fulfilling lives, thanks to breakthroughs in research and treatment.

years ago, kidney failure was a


Registered, non-dialysis kidney patients in BC Kidney disease patients on dialysis in BC OUR NETWORK





Form Follows Function

- Patients at centre of org chart
 - Health authorities responsible for program delivery
 - BCPRA provides overarching support for programs and is accountable to PHSA & MOH for outcomes




Provincial Committee Structure


- Multidisciplinary committees
- Cross-HA
 representation
- Annual work plans with clear deliverables
- Research, evaluation and CQI

BCPRA Committees

BCPRA Emergency Management Planning Committee BCPRA Executive Committee BCPRA Facilities & Equipment Planning Committee BCPRA Glomerulonephritis (GN) Committee BCPRA Hemodialysis Committee BCPRA Home Hemodialysis Care Committee BCPRA Kidney Care Committee BCPRA Medical Advisory Committee BCPRA Palliative Care Committee BCPRA Peritoneal Dialysis (PD) Committee BCPRA Renal Administrators Committee PROMIS Executive Steering Committee



Increased Access to Care: CKD/Non-Dialysis




CKD/Non-dialysis

2008 2018



Increased Access to Care: Dialysis



an a q e n c y of the Provincial Health Services Authority

2008 2018

A Renewed Strategic Plan





🛷 fraser health

island health

northern health

Interior Health

Working Together for Better Kidney Health

Our vision

People with kidney disease in BC have access to the highest quality, person-centred care, enabling them to live their lives to the fullest.

Our mission

The BC Renal Agency is responsible for the coordination and funding of outstanding kidney patient care, and acts as a catalyst for research, knowledge translation and innovation.

Our core values

People • Collaboration • Knowledge • Creativity • Team-Focused

Strategic Priorities 2018-2021







Innovation and research in renal care



Sustainable funding solutions



The right technology solutions




A sustainable renal community





Vancouver //



In the last province-wide patient experience survey, what percentage of BC kidney patients rated the overall quality of services as excellent or very good:

- a. 24%
- b. 75%

c. 82%





And the answer is:

b. 75%








Optimal patient experience and outcomes

PATIENT EXPERIENCE SURVEY



In 2016, the BC Renal Agency conducted a province-wide survey to measure patient perceptions about key areas of care. The survey was previously distributed to patients in 2009 and 2012.




Longitudinal patient experience data across the entire kidney population (13,000+)

PACIC-validated chronic disease survey tool (2009, 2012, 2016) Strategic Priorities 2018-2021



Optimal patient experience and outcomes






Managing Health Beyond Medical Care






Overall results of survey vary by modality



Priority matrix is used to identify areas for improvement in each modality









Optimal patient experience and outcomes

Next steps:

- Working with patients, provincial committees and renal programs to:
 - Review provincial, modality and HA data to establish common understanding of findings
 - Identify and implement practical changes
 - Advance culture change for person-centred care









Our Renal Research Mandate

- Facilitate/conduct quality research studies
- Knowledge translation
- Foster local, national and international research collaborations
- Facilitate training and mentoring of young physicians and scientists






5

Innovation and research in renal care


Our Research and Knowledge Translation Cycle






Strategic Priorities 2018-2021

Innovation and research in renal care





Between 2015-2017 how many journal articles were published by BC renal researchers?

a. < 50

b. > 50

C. > 100





And the answer is:

c. > 100 (117 to be precise)





Innovation and research in renal care

Knowledge Sharing & Translation: Publications and Presentations

Publications

	2013	2014	2015	2016	2017
Journal articles published by Division Members	37	38	33	47	37
Journal articles linked to project	6	7	6	7	7
Impact factor, median	2.85 [1.52, 9.197]	8.56 [3.58, 35.29]	4.98 [1.12, 8.56]	5.68 [4.12, 6.80]	4.1525 [2.37, 4.64]
Abstracts linked to project	16	7	9	6	7
Abstracts-oral presentations	2	4	1		

Q

Pub Med Search term

1 Full text

Prevalence-Based Targets Underestimate Home Dialysis Program Activity and Requirements for Growth.

Bevilacqua MU, et al. Perit Dial Int. 2018 May-Jun. Show full citation

Abstract

BACKGROUND: Many renal programs have targets to increase home dialysis prevalence. Data from a large Canadian home dialysis program were analyzed to determine if home dialysis prevalence accurately reflects program activity and whether prevalence-based assessments adequately reflect the

Pub Med Search term

1 Full text

Q

An update on the treatment of IgA nephropathy.

Review article

Barbour S. et al. Curr Opin Nephrol Hypertens, 2017. Show full citation

Abstract

PURPOSE OF REVIEW: The treatment of IgA nephropathy (IgAN) has been limited by several controversies in the literature, including the benefits of corticosteroids in addition to optimized

Original Article

External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for endstage kidney disease

Brian Forzley^{1,2}, Lee Er³, Helen HL Chiu³, Ognjenka Djurdjev³, Dan Martinusen⁴, Rachel C Carson^{1,4}, Gaylene Hargrove^{1,4}, Adeera Levin^{1,2} and Mohamud Karim^{1,3}

Abstract

Background: End-stage kidney disease is associated with poor prognosis. Health care professionals must be prepared to address end-of-life issues and identify those at high risk for dving. A 6-month mortality prediction model for patients on dialysis derived in the Linited States is used but has not been externally validated

PALLIATIVE

D The Authorith 201

001 10.1 177 Carrolla 177208

0.00

SSAGE

- Aim: We aimed to assess the external validity and clinical utility in an independent cohort in Canada. Design: We examined the performance of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model, using discrimination of the published 6-month mortality prediction model.
- decision curve analyses. Setting/participants: Data were derived from a cohort of 374 prevalent dialysis patients in two regions of British Columbia, Canada,
- which included serum abumin, are, peripheral vacular disease, dementia, and answers to the "the surprise question" ("Would I be surprised if this patient died within the next year?").

Results: The observed mortality in the validation cohort was 11.5% at 6 months. The prediction model had real (c-stat=0.70) but poor calibration (calibration-in-the-large=-0.53 (95% confidence interval: -0.88, -0.18); calibration slope=0.57 WSS confidence interval: 0.31, 0.83) in our data. Decision curve analysis showed the model only has added value in gading clinical decision in a small range of threshold probabilities: 8%-20%.

Conclusion: Depite reasonable discrimination, the prediction model has poor calibration in this external study cohort; thus, it may have limited clinical utility in settings outside of where it was derived. Decision curve analysis clarifies limitations in clinical utility not apparent by receiver operating characteristic curve analysis. This study highlights the importance of external validation of prediction models prior to routine use in citrical practice.



Brian Forzley^{1,2}, Helen H. L. Chiu³, Ognjenka Djurdjev³, Rachel C. Carson^{1,4}, Gaylene Hargrove^{1,4}, Dan Martinusen^{4,5}, and Mohamud Karim^{1,6}

Abstract

Background: Patients with end-stage renal disease (ISRD) frequently have a relatively poor prognosis with complex care needs that depend on prognosis. While many means of assessing prognosis are available, little is known about how Canadian nephrologists predict prognosis, whether they routinely share prognostic information with their patients, and how this information guides management.

Objective: To guide improvements in the management of patients with ESRD, we aimed to better understand how Canadian nephrologista consider prognosis during routine care.

Design and methodic A web-based multiple choice survey was designed, and administered to adult nephrologists in Carada through the e-mail list of the Casadian Society of Nephrology. The survey asked the respondents about their routine practice of estimating survival and the perceived importance of prognostic practices and tools in patients with ESRD. Descriptive statistics were used in analyzing the responses

Results: Lets than half of the respondents indicated they always or often make an explicit attempt to estimate and/or discuss survival with ESRD patients not on dialysis, and 25% reported they do so always or often with patients on dialysis. Survival estimation is most frequently based on clinical gestalt. Respondents endorse a wide range of issues that may be influenced by prognosis, including advance care planning, transplant referral, choice of dialysis access, medication management, and sideration of conservative care.

Limitations: This is a Canadian sample of self-reported behavior, which was not validated, and may be less generalizable to non-Canadian bealth care jurisdictions

Conclusions: In conclusion, prognostication of patients with ESRD is an important issue for nephrologists and impacts management in fairly sophisticated ways. Information sharing on prognosis may be suboptimal.

BCRenal MOBILIZING CULTURE CHANGE FOR QUALITY PALLIATIVE CARE IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN BRITISH COLUMBIA

Chu HHL¹, Hargrove GF, Saunders S¹, Dong J¹, Murphy-Bunke D¹, Daudev O¹, Levin A^{1,2}, Karm M² on behalf of the BCPRA Pallative Care Committee BC Provincial Renal Agency Vancouver, BC: Corportment of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC: CARADI

Results

Chronic kidney disease (CKD) is characterized by high symptom burden and poor life expectancy in advanced stage. Despite technological advances, mostality rates in patients with kidney disease remain high. An internated anomality in timely advance care planning and patilative care spanning the CKD care continuam is needed. · Working with the regional health authority renal programs (HARPs) of British Columbia (BC), Canada, the BC Provincial Renal Agency (BCPRA) funds and coordinates service

delivery across the province. In BC, as per the Patient Records and Outcome Management Information System (PROMIS), the mortality rates of patients who are on dialysis and not on dialysis remain quite stable over time. However more deaths over the years, especially

among non-dialysis patients, may have resource and operational implications.



Delivering quality renal pallative and end-of-life (EOL) care for renal patients is an important priority for the BC/PRA.



Implementation of the EOL Framework varies across the renal programs with each having formalized strategies to facilitate ongoing growth in palliative care. Prominent improvements have been shown in symptom care & management and advance care nianning. Symptom Assessment & Management

U.K.

a place of mind

More renal service units have adopted routine symptom assessment using the modified Edmonton Symptom Assessment System (mESAS) over the years Symptom assessment practice varies by HARP Nam-South Ad. PO. 1980



specific symptom management	t algorithms and intervention	8.
	umitals	100000
1		



5

Innovation and research in renal care

0

Careers

Knowledge Sharing & Translation: Website

Publications	
2018	+
2017	+
2016	+
2015	+
2014	+
2013	+
2012	+
2011	+

CRenal				Follow us	Search	
Kidney Services	Health Info	Research	About	Contact	Health Professionals	Donate

Our Research

Renal professionals across BC are engaged in a range of local, provincial and international research and quality improvement projects, many in collaboration with BC's educational institutions. Their work is frequently published in peer-reviewed journals.



Research Focus

About Our Research	>
Prevention and Early Detection	>
Living with Kidney Disease	>
Glomerulonephritis	>
Dialysis	>
Kidney Transplant	>
Palliative Care	>
Can-SOLVE CKD Network	>

Presentations 2018 + + 2017 2016 + + 2015 + 2014 + 2013 + 2012 ÷ 2011

Participate

Clinical Trials
Clinical Trials





Synergy: Largest kidney research grant in international history

- One of 5 chronic disease networks
- BCPRA is a collaborative partner: in-kind contributions
- Vision: By 2020, every Canadian with or at high risk for CKD will receive best recommended care, experience optimal outcomes, and have the change to participate in studies with new treatments
- Patients are partners throughout the research process:
 - research priority setting
 - study design and execution
 - dissemination and implementation of study results








Sustainable funding solutions

2018/19 renal budget: \$189.2 million

- Direct care, CKD and dialysis (equipment, supplies and services)
- Medications (accountability and transparency)
- Vendor contracts



- Hospitalizations
- OR utilization / Surgical procedures
- Radiology
- Lab services







Sustainable funding solutions

Activity-based funding model:

- Systems approach: multidisciplinary
- Funding follows patient
- Incentives: early intervention, self care
- Equitable access
- Reduced practice variation

- Patient projections methodology
- Apply modality distribution: CKD, PD, HHD, HD
- Apply resource management model

2.

3.








The right technology solutions




An Integrated, *Provincial* Clinical Information System Supporting clinical, administrative, QI and research activities



Strategic Priorities 2018-2021




The right technology solutions



PROMIS Patient Records and Outcome Management Information System

Touches Every Aspect of Patient Care







The right technology solutions

- March 2018: First release (4.0) on new platform
 - ESAS, modality selection, patient overview

July 2018: Second release (4.1)

- Patient registration, demographics, enrollment
- November 2018: Third release (4.2)
- New icons show if patient is enrolled in renal, transplant or cardiac
- Patient and physician searches improved
- New PD Assist and Classic centre reports added
- Patient chart pages can be printed or saved as PDFs
- New help link opens online PROMIS user guide



Development informed by input of Clinical Design Working Group:

PROMIS

2018

Highlights

 50 clinical stakeholders from across BC

Accountability: Indicators and Evaluation


- BCPRA provincial/national reporting
- Canadian Organ Replacement Registry (CORR)
- Ministry of Health
- PHSA Quality and Safety
- Reporting to Regional Programs:
- Clinical and management Indicators
- Finance reports actual costs, actual staff mix/FTEs by program
- Reporting for provincial modality committees and working groups
- Research support





Management Indicators Report Dashboard

Priority Strategies	Indicators	Status	Trend	Target	Prior FY16/17	Current FY17/18
Health and Well Being						
Targeted/effective primary dised	ise prevention and health promotion					
Ensure ongoing collaboration with provincial eGFR lab strategy and primary care	1. Level of Kidney Function (mean eGFR) at Time of CKD Registration	•	<i>→</i>	30-35 mL/min	29.4 mL/min	30.2 mL/min
Responsive and Effective Health	Care Services (Shift to Patient-Centered Ca	re)				
Comprehensive and Coordinated	Team-based Care					
Support best practice, dialysis care in BC	2. One-year Patient Survival Rate on Dialysis	•	→	≥80%	83%	83%
	3. Percentage of patients participating in independent dialysis (PD and home-based HD)	A	÷	≥31.5%	30.8%	31.0%
Promote and support initiation	4. Peritoneal Dialysis Intake Rate	٠	→	≥25%	34.7%	34.9%
of transitions in care to the appropriate modality	5. One-year Peritoneal Dialysis Attrition Rate	•	→	≤30%	30%	30%
	6. Rapid Progression of Kidney Function	•	↑	TBD	23.19	Renewed role of
	7. Level of Kidney Function at Dialysis Initiation	•	→	≤15 mL/min	10.2 mL/m	Collaborate with



• Mapped to MOH and PHSA strategic priorities

Set Targets	<	
	MEASURE	sace review

				,	,	,
	8. Percentage of chronic kidney disease					
	patients followed according to		¥	≥70%	72 104	70.3%
	standardized clinical pathway for	•			/2.170	70.570
ollaborate with specialists to	hemodialysis access creation					
	9. Percentage of patients initiating					
• • •	hemodialysis with appropriate access (= %	•	1	≥25%	24.7%	28.8%
01 C	incident fistula)					
	10. Percentage of prevalent HD patients					
	dialyzed with optimal access (=%	•	÷	>60%	51.4%	51.1%
	prevalent fistula)					
mprove outcomes, reduce hospit	talizations					
	11a. Bacteremia infection rate per HD	•	J.	<0.5 per HD	0.049	0.067
	Catheter access year	-		Cath Year	0.045	0.007
	11b. Bacteremia infection rate per HD		<u>د</u>	<0.5 per HD	0.005	0.006
mprove quality of dialycis care	Fistula access year			Fistula Year	0.005	0.000
inprove quality of ularysis care	11c. Bacteremia infection rate per HD	•	al.	<0.5 per HD	0.033	0.067
	Graft access year	•	*	Graft Year	0.022	0.067
	11d. Peritonitis infection rate per PD		al.	<0.5 per PD		
	patient-year	•	*	Pt-Year	0.282	0.311
insure Value for Money						
nabling IMIT and technology inf	frastructure and approaches to funding					
evelop multi-year application						
	12. Percentage of patients with modality	•	->	TBD	89%	88%
	selection available in PROMIS				5576	00/0
	tenewed role of hospitals - focus collaborate with specialists to mprove access and quality of are mprove outcomes, reduce hospit mprove quality of dialysis care nsure Value for Money	patients followed according to standardized clinical pathway for hemodialysis access creation 9. Percentage of patients initiating hemodialysis with appropriate access (= % incident fistula) 10. Percentage of prevalent HD patients dialyzed with optimal access (= % prevalent fistula) 11a. Bacteremia infection rate per HD Catheter access year 11b. Bacteremia infection rate per HD Fistula access year 11c. Bacteremia infection rate per HD Graft access year 11d. Peritonitis infection rate per PD patient-year nesure Value for Money Hevelop multi-year application oadmap and implementation 12. Percentage of patients with modality selection available in PROMIS	Intervent of the splitals - focus on improved surgical services 8. Percentage of chronic kidney disease patients followed according to standardized clinical pathway for hemodialysis status access creation 9. Percentage of patients initiating hemodialysis with appropriate access [%] incident fistula) 10. Percentage of prevalent HD patients dialyzed with optimal access [=%] mprove outcomes, reduce hospitalizations 11. Bacteremia infection rate per HD Catheter access year 11. Bacteremia infection rate per HD Fistula access year 11. Bacteremia infection rate per HD Graft access year 11. Bacteremia infection rate per HD Fistula access year 11. Bacteremia infection rate per HD Graft access year 11. Perionitis infection rate per PD patient-year nesure Value for Money nobing IMIT and technology infrastructure and approaches to funding tevelop multi-year application oadmap and implementation	tenewed role of hospitals - focus on improved surgical services 8. Percentage of chronic kidney disease patients followed according to standardized clinical pathway for hemodialysis access creation y percentage of patients initiating hemodialysis with appropriate access (= % incident fistula) 10. Percentage of prevalent HD patients dialyzed with optimal access (= % prevalent fistula) tal. Bacteremia infection rate per HD catheter access year tal. Bacteremia infection rate per HD tal. Peritonitis infection rate per PD tal. Peritonitis inf	tenewed role of hospitals - focus on improved surgical services 8. Percentage of chronic kidney disease patients followed according to standardized clinical pathway for hemodialysis access creation ↓ ≥70% themodialysis access creation Percentage of patients initiating hemodialysis access creation Percentage of patients initiating hemodialysis with appropriate access (= % ↑ ≥25% incident fistula) Dercentage of prevalent HD patients dialyzed with optimal access (=% → >60% prevalent fistula) mprove outcomes, reduce hospitalizations access year 11a. Bacteremia infection rate per HD ↓ Catheter access year Graft access year Percentage of patients infection rate per HD ↓ 	tenewed role of hospitals - focus on improved surgical services 8. Percentage of chronic kidney disease patients followed according to standardized clinical pathway for hemodialysis access creation Percentage of patients initiating hemodialysis access creation Percentage of patients initiating hemodialysis with appropriate access (= % A 225% Percentage of prevalent HD patients dialyzed with optimal access (= % A 225% Standardized clinical pathway for Percentage of prevalent HD patients dialyzed with optimal access (= % A 225% Standardized prevalent HD patients dialyzed with optimal access (= % A 20.5 per HD Cath Year Bacteremia infection rate per HD Cath Year Stata access year Bacteremia infection rate per HD Cath Year Stata access year Bacteremia infection rate per HD Cath Year Cath Year Conspective access year Bacteremia infection rate per HD Cath Year Conspective access year Bacteremia infection rate per HD Cath Year Conspective access year Per HD Cath Year Conspective access year Percentage of patients infection rate per PD Conspective access year <li< td=""></li<>

Provincial Accomplishments: *Highlights*

- Only province with systematic symptom assessment (modified ESAS)
 - Protocols and symptom guides
 - Patient teaching handouts and pharmacy info sheets
- First-in-kind programs
 - Pharmacy formularies (most extensive financial support in Canada)
 - GN network and registry
 - PKD registry (1,000 patients)
 - Provincial PD assist service
 - TB Screening for all new dialysis patients
- In development: transition algorithms & patient guides


symptoms over time. The	ECKLIST are been understand and monitor your is deexisting as so this inter more term on the differ side of the term,	PATIENT INFO Nature Address Phane Title	RMATION/LABO	R.		More hlights in
with each symptom. No pain	(DO-MON-YYYY) RQLMI) or that best describes how you have b Seeks 3 + no symptom 10+ the worst poor 1 1 2 3 4 5 4	sible for the symptom	Worst possible	-		oday's ovincial
National Content laws in services in the content laws in the services in the content laws in the services in the services in the services content in the services content in the services in the services in the service in the services in the service in the services in the services in the service in the service in the services in the service in the service in the service in the service in the service in the service in the service in the service in	1 3 3 4 8 4 1 2 3 4 8 4 1 2 3 4 6 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 3 4 5 4 1 2 2 4 6 4 2 2 4 6 6 6 1 2 2 4 6 6 1 2 2 4 6 6 1 2		Word possible Wedness Word possible More possible More possible words Word possible words Word possible Word possible			ommittee oowcase
This sector to be complete base complete to prove O Partie O Day Tean Nambe Asse O Parter San Nambe Asse O Parter set and Parter set and	Tale programs notes for follow up on Core plant up beind Theode entered in FRCARS	2 8 8 8 44444 10112	World possible symplem	Symptom Assessmen Manageme		
DERenal P	ADPKD Reg	istry	There is an	Vy Symptom Checklist (me Punjabi Traditional Chinese Simplified Chinese Large-Print English My Symptom Checklist Info	odified ESAS)	PROVINCIAL STANDARDS &
	Tolvaptan for <i>i</i>	ADPKD		Sheet (Staff/ Physician) Common Sympton	n Guides	Tuberculosis Scr F
registry Columb regardle	developed a first that aims to incl ians with polycys ess of disease or	ude all B stic disea treatmer	ritish se, nt	Constipation Depression and An	+ nxiety +	Approvale to Approx
made a	The comprehensivailable through the second s	the regist	ry will	Q Search		Menu 🗏
care and the dise	t improved individ d improve our un ease, which will b	derstand enefit all	ing of	Glomeru	In this se	
S				he GN network & re		•

The GN network & registry aims to improve our understanding and treatment of glomerulonephritis.

Regional Innovations

- Multiple quality improvement initiatives across HAs:
 - Funded through 'value add'
 \$\$ (see handouts and BCKD app)
 - Posters at BCKD







Transplant First Initiative

Transplant First is a joint initiative between the BC Renal Agency's Kidney

Care Committee and BC Transplant to promote pre-emptive transplants for

patients considering renal replacement therapies. Pre-emptive transplants

are those that occur before the person requires dialysis therapy to start.

The focus of the initiative, launched in October 2017, is to promote living

donation, which involves patients recruiting volunteer kidney donors. A

a range of patient and provider support materials were developed. Print

and video resources can be accessed on the BC Transplant and BC Renal

Agency websites (go to www.bcrenalagency.ca, click on Health Info or

Value-added dollars continue to support ongoing development of the

search functionality. New information and tools for patients and care

PROMIS is an integrated, provincial information system for renal and

time, accurate data to over 1,500 users, supporting a broad range of

on two key outcomes: better health for kidney and transplant patients.

and the best use of healthcare resources. The PROMIS team, working

with a clinical design working group of 50+ stakeholders from all health

authority renal programs, continues to work on a comprehensive rebuild

transplant care provided to over 22,500 patients in BC. It provides real-

clinical, administrative, OI and research activities, all of which are focused

BC Renal Agency's website, to ensure intuitive navigation and enhanced

teams are added to the website on a regular basis, as well as our YouTube

channel. In fact, our most popular documents have been viewed between

Health Professionals and then select Transplant).

30.000-50.000 times over the past two years.

PROMIS Enhancement

Agency Website

provincial coordinator was hired to support the kidney care clinics and

Although a portion of these funds is used to support cross provincial initiatives of the BC renal network, the majority is allocated to health authority renal programs to meet diverse needs at the local level.

At the provincial level, funds were used for a number of projects almed at improving delivery of care and supporting future program development and sustainability.

Patient Education Tools

Vibue-added dollars continue to support the development and enhancement of a range of platent education materials that premote patient self-magnetiment and improve heads outcomes. In 2017/8, these included patient handback and tools on a range of topics, including classiss and torrel, home dailysis, det and multitors, self-carnelation and symptom assessment and management.

Patient Experience Survey

Value-scied dollars from industry previously sopported a patient separetors survey of a fregisteric followy potents (F3,000⁻¹) in the province. Results of the survey have since been analyzed, with provincial and modally-specific exposits completed, published on the agency's webbie and discontration (which the result community, Far of high-level overview, refer to the survey infographic on the BCPAR webbie. Next tages include completed in their all authority specific reports and working with patients and care teams to sterify opportunities for improvement, instances suits a tradition of their autorities for improvement, and undergin measure inform strategic decision enabling and longterm Kintey care planning, evaluation of the overall system's performance and undergin measure inforts.

AMGEN' Baxter



Value-Added Dollars from PD Contract Support Innovation, Improve Peritoneal Dialysis Care

BCRenal

Highlights from 2017-20

From projects locused on promoting independence through home throughout to ethnanced patient and staff extraction, valueadded funds from a provincial contract-negotabade by the BC Remail Agence (and Provincial Health Services Authority Supply Chain improved care for pentionsal dialysis PD patients and quality of work fiel for dividences across SC.

Baxter

While a portion of these funds is used at the provincial level to support PD latitatives of the ID createl network, the najiority is allocated to health authority PD programs the need diverse needs at the local level. Collectively the objective is to optimize the prevalence of PD throughout BC, and to ensure quality PD patient care and enhanced shaff knowledge and excertise.

Enhancing PD Care Across BC

The BC Renal Agency is dedicated to ensuring all end-stage renal patients are considered for home thereighes, in 2017/88, value-added funds were used to support initiatives almed at increasing PD uptake across health authority programs, as well as to ensure high quality care.

PD Assist Provincial Program

The solout of the PO Assist program to all health authority renal programs in BC was completed in 2018, PO Assist, which includes both respite and long-term assistance options, supports frail pertinned dailysis patients who need help to maintain their PO care. The program has seen steady growth since it is launch and had over 60 patients as of spring 2018.

PD Assist was recognized by the BC Patient Safety and Quality Courcil with the 2017 Excelence in Quality – Living with Illiness Award, and has been published in Peritoneal Dialysis International and the European Journal for Person Centred Healthcare. Benefits of the provincial PDA program include:

- alowing frail PD patients to continue dialysis at home vs transferring
 to higher cost facility-based hemodialysis;
 similar or lower rates of peritoritis in this high risk population (a
- costly and sometimes devastating complication of PD);
 respite care for acute situations (ns hospitalization or transfer to homodialvis);
- support for patients nearing end of life to allow planning to take

place at home, as opposed to in hospital or after a costly and disruptive transfer to hemodialysis; and

patient-centred delivery of care.

The program represents an innovative and efficient way to use existing resources to provide enhanced patient care.

Standardized PD Guidelines, Procedures and Patient Materials

PD value-added funds support the organiz development of provincial PD marsing guidelines and the convesponding productial implementation of standardsold procedures and tools. To 2017/8 this included a Bert Practices Guideline for PD programs, development of PD travial imburnation and letters for pasters. It handhoid is assomed tool to determine if patients are ready to perform and manage their PD care, as well as proceedings to inigition, cathetine flow, cathetine hepativization and capping surgical insists and varimm [50 sublicities].

In addition, PD value-added funds supported work to update and revise PD patient training + endules: and videos available through the BCHRA website Guidelines, procedures and various patient and provider tools can be found on the BC Benal Agency's website (www.btensilagency.cia) in the PD sections under 'Health Professionals' and Health Info'.

Patient Attendance at ISPD

PD value-added funds were used to support the path(pation of several patients at the international Society of Perticental Dialysis compress that took place in Nacouver in May 2008. This was a rare opportunity for BC PD patients to attend and see the inner workings of one of the world's most important conferences on pertoneal dialysis that brings together leading enhicities in the feld to mail round the world.

Provincial Committee Participation

Sharing outcomes with provincial renal partners through the BC Renal Agency's network of committees can guide and consolidate practice. It

is Care

Emergency Response

- Wildfires and other climate-related events are an ongoing challenge
- Renal Emergency Management Committee:
 - Maintaining & implementing provincial renal emergency response plans
 - Ongoing promotion and education: Emergency prep month May

VANCOUVER SUN

B.C. wildfires 2018: This season now second worst in province's history

BY THE CANADIAN PRESS ORIGINALLY PUBLISHED: AUG 26, 2018







Public Outreach & Awareness

- ➢ World Kidney Day/Kidney Smart Campaigns
 - Social media
 - Facebook advertising
 - #KidneyHealthChallenge
 - Advertising: Van Sun/Province, public transit, ethnic media
 - WKD promotion
 - "Day at Dialysis" social media event



Kidney Health Self-Assessment



Are your kidneys healthy? People can have kidney disease without being aware of it. There are often no symptoms until the disease is quite far along. Research has shown that scome people are at higher risk forkling disease. They should have their kidneys checked even if they feel well. Take this test to find out if you should have your kidneys checked. Start quiz



Punjabi and Chinese versions













а.

b.

C.

Over a two-year period, which of these documents was the most accessed from the BCPRA website?

- Antidepressant use in Adults with CKD
- Diabetes Kidney-Friendly Shopping List
- Cleaning and Disinfecting HD Machines/Stations



Diabetes Kidney-Friendly Shopping List

May 2016 Created by the BC Renal Registered Dietitian's Group





ANTIDEPRESSANT USE IN ADULTS WITH Chronic Kidney Disease BC

Your patient has dreave kidney deesse (CKD). This hendout provides information about doosing adjustments i required. The information is provided as a guide. If you have a patient specific question, please contact your p or care learn. Here internees was bound in the full guideline, "Opposite and Analoy. The Rels of Killerg Dave Chine" as


AN/NURSE PRACTITIONED INFORMATION SHEET

		Desing adjust	nent in renal failure		
Medications	eGFR 30-60 est/min	eGFR 15-30 mL/ min	eGFR less than 15 mUmin	Diatysta (PD or HD)	Conces
			1" line therapie		
		Selective 5	erotonin Reuptake I	Inhibitors (55PB	
Cluispran	No adjustment	No adjustment	No adjustment	No adjustment (HD: not removed)	Riak of GTc protorgatori (mak il) regislay or 50 mg/day with alrong CYP2C19 hishotech") Hall as potent as excitationary, therefore NOT interchangeable
Excite/opram	No adjustment	SD: 10 mg/day	SD 10 mg/day	SD: 10 mg/day	 Riak of QTc petiorgetion Twice as potent as citalopram, therefore NOT interchangeable
Plucastre.	No atjustment	No adjustment	No adjustment	No adustriant	Risk of QTc pickergation
Revenance	No adjustment	No adjustment	No adjustment	No adjustment	Many potential drug interactions Most neurosoting/seducing CEPII

Cleaning & Disinfecting Hemodialysis Machines & Stations

Created: August 2016 Approved by the BCPRA Herrodialysis Committe

an a gency of the Provincial Health Services Authorit



And the answer is...

c. Cleaning and Disinfecting HD Machines/Stations



Cleaning & Disinfecting Hemodialysis Machines & Stations

Approved by the BCPRA Hernodialysis Committee

ANTIDEPRESSANT USE IN ADULTS WITH CHRONIC KIDNEY DISEASE

Your patient has chronic koney disases (CKD). This handout provides information about dosing adjustments if antidepressants are recurrise. The information is provided as is guide. If you have a patient pocklic question, seleand control your patient's individual or care team information and the user in the ultigrature. Devision and knowly: Tak New All Know Care Chronic Store boundage/you.

BCRenal

35,702

Vedications	Doeing adjustment in renal failure				
	eGFR 30-60 etUnin	eGPR 15-30 mL/	sGPR less than 15 million	Distysis (PD or HD)	Connenta
			1" line therapie		
		Delective D	erotanin Peuplake I	inhibitore (55R)	
Otsioprare	No adustment	No adjustment	No adjustment	No adjustment d-D: net removed	Rek of CTc protongation (max 4) mg/day or 50 mg/day with strong CVP2CT3 (whotever) Nat as potent are exclassionary, therefore NCT interchangeable
Eaclaignee	No aduatment	SD: 10 regiliev	30.10 og/dev	SD: 10 mg/dey	Risk of OTc prolongation Twice as potent as citationant, therefore NOT interchangeable
Russetre	No adjustment	No adjustment	No adjustment	No adjustment	 Risk of DTc prolongation
Puvesarine	No adjustment	No adjustment	No adjustment	No adjustment	Many polential drug interactions Most neucosting/sedating SERI



Diabetes Kidney-Friendly Shopping List

May 2016 Created by the BC Renal Registered Diettian's Group






23,364

Make use of our Website and YouTube Resources

bcrenalagency.ca



Youtube.com/BCRenalAgency

- Over 150 videos
- Almost 300,000 views



Follow us on Twitter and Facebook

BCRenalAgency



Facebook.com/BCRenalAgency







A sustainable renal community

How long have you been involved in renal or kidney transplant care?

- a. Less than two years
- b. 2 10 years
 - 10 20 years
- d. 20+ years

C.







A sustainable renal community

PRA and UBC supported Advanced Training Fellowships (ANT)

- Clinical Fellowships support of UBC training program
 - Ibrahim Ismail ANT
 - Susie Hewitt ANT, Home Hemo/PD
 - Jenny Chen Home Hemo/PD
 - Kris Poinen Home Hemo/PD
- Post Doctoral Fellowships
 - Mark Canney Research
- Administrative Fellowship
 - Peter Birks







A sustainable renal community

Welcome

Adult Nephrology

Core Training Neph Fellows

- Abdul Alkandari (Y2)
- Justin Gill (Y2)
- Priya Jindal (Y2)
- Aiza Waheed (Y2)
- Amanda Cunningham (Y1)
- Marianne Park (Y1)
- Tae Won Yi (Y1)

Pediatric Nephrology

- Pratichi Kadam
- Blake Sandery
- Kayla Flood
- Kristen Favel

New Nephrologists

- Claire Harris
- Aleisha Hatakka
- Morgan Lam
- Elizabeth Lee





- BC Patient Safety and Quality Council 2018 Quality Award, Coping with End of Life Category: BCPRA's Palliative Care Committee
- UBC Department of Medicine 2018 Clinical Teaching Excellence Award, Honour Roll: Drs. Monica Beaulieu, James Lan and Gerald DaRoza
- Canadian Society of Transplantation 2018 Research Excellence Award: Dr. Jag Gill
- UBC Dean Kehler letter for Outstanding Academic Performance: Dr. Sean Barbour
- BC Health Care Awards, 2018 Dianna Mah-Jones Award of Excellence, Person-Centred Care: Aimee Morry and Eileen Carolan





for your energy & commitment to people living with kidney disease


- Over 300 people actively involved in our network:
- All health care team members directly contribute to patient wellness
- The BCPRA is us, working together






Next up: Provincial Committee Showcase

- 9:00-9:20am Kidney Care Committee
 - Dr. Monica Beaulieu
- 9:20-9:40am Hemodialysis Committee
 - Dr. John Antonsen
- 9:40-10:00am Peritoneal Dialysis Committee
 - Dr. Suneet Singh
- Break
- 10:30-10:50am Home Hemodialysis Committee
 - Dr. Michael Copland



10:30am

🖸 10:30am - 10:50am	Parq Ballroom
Provincial Committe	e Update - HHD>
Plenary	



Your feedback is important! Use the BCKD app!



Personalized Kidney Care

Enjoy the conference!